
Overview
Nutritional supplements maker's fiscal Q4 net sales rose 6% yr/yr
Adjusted diluted EPS for fiscal Q4 fell 6% yr/yr
Company anticipates flat to 8% growth in fiscal 2026 net sales
Outlook
USANA projects fiscal 2026 consolidated net sales between $925 mln and $1 bln
Company expects fiscal 2026 net earnings between $20.3 mln and $26.6 mln
USANA anticipates Hiya net sales of $140 mln to $155 mln in fiscal 2026
Result Drivers
CUSTOMER STABILIZATION - Co noted signs of stabilization in active customer counts in core nutritional business, with modest sequential sales growth in key markets like China, US, and Canada
OMNICHANNEL GROWTH - Hiya and Rise brands experienced solid year-over-year growth, contributing to overall sales increase
CORE BUSINESS DECLINE - Core nutritional business sales fell 8% in FY 2025, reflecting challenges in customer acquisition
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS |
| -$0.10 |
|
Analyst Coverage
Wall Street's median 12-month price target for USANA Health Sciences Inc is $39.00, about 86.6% above its February 13 closing price of $20.90
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago
Press Release: ID:nBw7jfm7Ka
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.